AstraZeneca Annual Report and Financial Statements 84 Form 20-F Information 2004 Notes to the Financial Statements continued 6Dividends to shareholders 2004 2003 2002 2004 2003 2002 Per Per Per share share share $m $m $m Interim, paid on 20 September 2004 $0.295 $0.255 $0.230 494 436 398 Second interim, to be confirmed as final, payable 21 March 2005 $0.645 $0.540 $0.470 1,061 914 808 $0.940 $0.795 $0.700 1,555 1,350 1,206 7 Earnings per $0.25 Ordinary Share 2004 2003 2002 Net profit for the financial year before exceptional items $m 3,527 3,036 3,186 Exceptional items after tax $m see Note 3 286 350 Net profit for the financial year $m 3,813 3,036 2,836 Earnings per Ordinary Share before exceptional items $2.11 $1.78 $1.84 Earnings loss per Ordinary Share on exceptional items $0.17 $0.20 Earnings per Ordinary Share $2.28 $1.78 $1.64 Diluted earnings per Ordinary Share before exceptional items $2.11 $1.78 $1.84 Diluted earnings loss per Ordinary Share on exceptional items $0.17 $0.20 Diluted earnings per Ordinary Share $2.28 $1.78 $1.64 Weighted average number of Ordinary Shares in issue for basic earnings millions 1,673 1,709 1,733 Dilutive impact of share options outstanding millions 2 32 Diluted average number of Ordinary Shares in issue millions 1,675 1,712 1,735 There are no options, warrants or rights outstanding in respect of unissued shares except for employee share option schemes.
The number of options outstanding and the weighted average exercise price of these options is shown in Note 29.
The earnings figures used in the calculations above are unchanged for diluted earnings per Ordinary Share.
Earnings per Ordinary Share before exceptional items have been calculated to eliminate the impact of exceptional items on the results of the business.
